€15.10
1.34%
Xetra, Dec 29, 05:35 pm CET
ISIN
DE000A3ENQ51
Symbol
1SXP
Index

SCHOTT Pharma Stock price

€15.10
-3.82 20.19% 1M
-13.35 46.92% 6M
-10.06 39.98% YTD
-10.06 39.98% 1Y
-16.20 51.76% 3Y
-16.20 51.76% 5Y
-16.20 51.76% 10Y
-16.20 51.76% 20Y
Xetra, Closing price Mon, Dec 29 2025
+0.20 1.34%
ISIN
DE000A3ENQ51
Symbol
1SXP
Index

New AI Insights on SCHOTT Pharma Insights AI Insights on SCHOTT Pharma

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€2.2b
Enterprise Value
€2.3b
Net debt
€51.7m
Cash
€33.9m
Shares outstanding
150.6m
Valuation (TTM | estimate)
P/E
15.6 | 14.7
P/S
2.3 | 2.1
EV/Sales
2.3 | 2.2
EV/FCF
65.3
P/B
2.5
Dividends
DPS
€0.18
Yield 1Y | 5Y
1.2% | 0.4%
Growth 1Y | 5Y
12.5% | -
Payout 1Y | 3Y
16.5% | 10.4%
Increased
3 Years
Financials (TTM | estimate)
Revenue
€986.2m | €1.0b
EBITDA
€266.4m | €309.9m
EBIT
€186.9m | €226.6m
Net Income
€146.5m | €154.5m
Free Cash Flow
€35.2m
Growth (TTM | estimate)
Revenue
3.0% | 6.2%
EBITDA
9.8% | 16.4%
EBIT
5.2% | 21.2%
Net Income
-2.0% | 5.5%
Free Cash Flow
-56.1%
Margin (TTM | estimate)
Gross
33.7%
EBITDA
27.0% | 29.6%
EBIT
19.0%
Net
14.9% | 14.8%
Free Cash Flow
3.6%
Financial Health
Equity Ratio
55.8%
Return on Equity
16.4%
ROCE
16.3%
ROIC
12.6%
Debt/Equity
0.1
More
EPS
€1.0
FCF per Share
€0.2
Short interest
-
Employees
5k
Rev per Employee
€210.0k
Show more

Is SCHOTT Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

SCHOTT Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a SCHOTT Pharma forecast:

16x Buy
84%
2x Hold
11%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a SCHOTT Pharma forecast:

Buy
84%
Hold
11%
Sell
5%

Financial data from SCHOTT Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
986 986
3% 3%
100%
- Direct Costs 654 654
3% 3%
66%
332 332
3% 3%
34%
- Selling and Administrative Expenses 130 130
4% 4%
13%
- Research and Development Expense 28 28
15% 15%
3%
266 266
10% 10%
27%
- Depreciation and Amortization 79 79
22% 22%
8%
EBIT (Operating Income) EBIT 187 187
5% 5%
19%
Net Profit 146 146
2% 2%
15%

In millions EUR.

Don't miss a Thing! We will send you all news about SCHOTT Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCHOTT Pharma Stock News

AD HOC NEWS
25 days ago
Laut Analysten schwache Ziele von Schott Pharma DE000A3ENQ51 für 2026 und darüber hinaus haben die Aktien am Freitag belastet.
AD HOC NEWS
26 days ago
SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51
AD HOC NEWS
26 days ago
Der Pharmazulieferer Schott Pharma DE000A3ENQ51 kämpft weiter mit der Marktunsicherheit und nimmt sich für das neue Geschäftsjahr überraschend niedrige Umsatzziele vor.
More SCHOTT Pharma News

Company Profile

Head office Germany
CEO Andreas Reisse
Employees 4,775
Founded 2022
Website www.schott-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today